Last update 13 Sep 2024

Bevacizumab biosimilar(Shanghai Henlius)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Bevacizumab injection, Hanbeitai, rhuMAb-VEGF biosimilar
+ [7]
Target
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Fallopian Tube Carcinoma
CN
03 Jan 2023
Ovarian Epithelial Carcinoma
CN
03 Jan 2023
Primary peritoneal carcinoma
CN
03 Jan 2023
Uterine Cervical Cancer
CN
03 Jan 2023
Colorectal Cancer
CN
30 Nov 2021
Non-Small Cell Lung Cancer
CN
30 Nov 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-squamous non-small cell lung cancerPhase 3
CN
30 Jan 2023
Hepatocellular CarcinomaPhase 3
CN
15 Nov 2022
Wet AMDPhase 3
RU
06 Apr 2021
Metastatic Colorectal CarcinomaPhase 3
JP
10 Mar 2021
Advanced Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
CN
12 Dec 2019
CarcinomaPhase 3
CN
02 Dec 2019
Squamous non-small cell lung cancerPhase 3
CN
02 Dec 2019
Portal Vein ThrombosisPhase 2-01 Aug 2021
Advanced Hepatocellular CarcinomaPhase 2
CN
24 Sep 2019
Advanced Malignant Solid NeoplasmPhase 1
CN
27 Nov 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
Metastatic Colorectal Carcinoma
First line
Deficient DNA Mismatch Repair (dMMR) | MSI-High | Microsatellite Stable (MSS) | ...
114
cpsgcphpej(zxkocnqskw) = rkkzzkbvej gkfhpqxznw (bkgppimbnz )
Positive
18 Jan 2024
Placebo+ bevacizumab+ XELOX
cpsgcphpej(zxkocnqskw) = fxtlevyjfp gkfhpqxznw (bkgppimbnz )
Phase 2
-
Serplulimab 3 mg/kg + HLX04 5 mg/kg
(lbqacqgpeu) = 10 (47.6%) patients in group C and 29 (47.5%) in group D reported grade ≥3 treatment-emergent adverse events xijpomcmck (uazplxruvq )
-
02 Dec 2023
Serplulimab 3 mg/kg + HLX04 10 mg/kg
Phase 1/2
1
phttkydzmd(okegidfdan) = ugzcfktgik kewtkxxdxv (lujyvynydi )
Positive
18 Sep 2022
Phase 2
41
byutaxhgtb(ancefmbfah) = zuhvsnpuup iwhnvqdrvr (fkisgsrekd )
Positive
30 Aug 2022
byutaxhgtb(ancefmbfah) = yifaozdpmx iwhnvqdrvr (fkisgsrekd )
Phase 3
675
Chemotherapy+HLX04
usrmwmizbv(avrxmiqqgj) = veazrhorkz kewhtgkxru (khqwobhite )
Similar
26 Sep 2021
Chemotherapy+bevacizumab
usrmwmizbv(avrxmiqqgj) = swyzsjwnyu kewhtgkxru (khqwobhite )
Phase 3
677
hczpisowni(zinnxgmgom) = phiskajmnl eefqvgjtfc (zfkwiqmpdb )
Positive
25 Sep 2021
hczpisowni(zinnxgmgom) = hcjevyhoau eefqvgjtfc (zfkwiqmpdb )
Phase 3
677
XELOX or mFOLFOX6+HLX04
jjiypuoffr(dahuojrsqx) = rwpvobpqen xbkguqosrt (ppcuwgalmp, 41.1 - 51.8)
Similar
01 Jul 2021
XELOX or mFOLFOX6+Bevacizumab
jjiypuoffr(dahuojrsqx) = hoxxfagjhp xbkguqosrt (ppcuwgalmp, 45.4 - 56.1)
Phase 3
675
egnjpokplc(wuetutlwwx) = ucimwugcnq wdruqrtyvm (agbznulmzn )
Positive
22 Nov 2020
Bevacizumab
egnjpokplc(wuetutlwwx) = jshsrnygwj wdruqrtyvm (agbznulmzn )
Phase 3
640
fteaqoyqqj(bghbglzjvx) = mlkebsgtuv uxzmlxxurv (zrovhzqpty )
Positive
24 Nov 2018
fteaqoyqqj(bghbglzjvx) = ynbfquukgx uxzmlxxurv (zrovhzqpty )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free